Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILOR-400 vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular c AMP and c GMP, resulting in bronchodilation and vasodilation.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
FDA-approved: Symptomatic management of chronic obstructive pulmonary disease (COPD) and other bronchospastic disorders.,Off-label: Treatment of bronchial asthma, pulmonary hypertension, and as an adjunct in heart failure.
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Hepatic metabolism via CYP1A2, CYP3A4, and CYP2E1; undergoes N-demethylation and oxidation to inactive metabolites.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal (70% unchanged), hepatic metabolism (30%)
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
40% bound, primarily to albumin
92-96%, primarily to albumin and alpha-1-acid glycoprotein
0.5 L/kg (approximates total body water; indicates distribution into extracellular fluid)
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral: 95-100% (well absorbed from gastrointestinal tract)
Oral: 40-50%; Inhalation: 20-30%
GFR 10-50 m L/min: 400 mg every 8-12 hours; GFR <10 m L/min: 400 mg every 12-24 hours.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: 400 mg every 8-12 hours; Child-Pugh Class C: 400 mg every 12-24 hours.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
6 months to 2 years: 8-12 mg/kg/day divided every 6 hours; 2-12 years: 12-16 mg/kg/day divided every 6 hours; maximum 600 mg/day.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Start at lower end of dosing range (400 mg every 8 hours) and titrate based on renal function and tolerability.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
None.
No FDA black box warning.
Cardiovascular: May cause hypotension, tachycardia, or arrhythmias; use with caution in patients with cardiovascular disease.,CNS: May cause insomnia, anxiety, or seizures; adjust dose in elderly or with hepatic impairment.,Renal: Excreted largely unchanged; caution in renal impairment.,Drug interactions: Increased toxicity with cimetidine, ciprofloxacin, and others that inhibit CYP1A2.
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to dyphylline or any xanthine derivative.,Acute myocardial infarction.,Hypotension.,Uncontrolled arrhythmias.
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
Avoid high-caffeine foods (coffee, tea, cola, chocolate) as they increase risk of side effects. Charcoal-broiled foods may decrease drug absorption. High-fat meals may delay absorption; take on an empty stomach for consistent effect.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
Teratogenic potential: Pregnancy Category C. First trimester: Limited human data, animal studies show fetal toxicity at high doses. Second and third trimesters: Potential for transient neonatal hypoglycemia, tachycardia, and irritability due to maternal xanthine exposure. Avoid use unless benefit outweighs risk.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Diphylline (active ingredient) is excreted into breast milk. M/P ratio not established. Potential for irritability and sleep disturbance in infants. Caution advised; consider alternative therapies.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
No well-established pharmacokinetic studies in pregnancy. However, plasma clearance of xanthines may decrease in late pregnancy due to reduced hepatic metabolism. Consider monitoring drug levels and adjusting dose to maintain therapeutic range. Initiate at lower end of dosing, titrate based on response and toxicity.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
DILOR-400 (diprophylline) is a xanthine bronchodilator with similar efficacy to theophylline but with reduced central nervous system stimulation. Monitor serum levels for therapeutic range (10-20 mcg/m L). Caution in patients with peptic ulcer disease, hyperthyroidism, or seizure disorders. Adjust dose in hepatic impairment and elderly. Avoid concurrent use with other xanthines.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take exactly as prescribed; do not exceed recommended dose.,Do not crush or chew extended-release tablets.,Report nausea, vomiting, palpitations, or seizures immediately.,Avoid caffeine-containing foods and beverages.,Do not smoke or stop smoking without consulting doctor as dose may need adjustment.,Keep a regular dosing schedule; do not double up missed doses.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILOR-400 vs AEROLATE III, answered by our medical review team.
DILOR-400 is a Bronchodilator that works by Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular c AMP and c GMP, resulting in bronchodilation and vasodilation.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILOR-400 and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILOR-400 is: 400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DILOR-400 and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DILOR-400 is classified as Category C. Teratogenic potential: Pregnancy Category C. First trimester: Limited human data, animal studies show fetal toxicity at high doses. Second and third trimesters: Potential for trans. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.